Source:http://linkedlifedata.com/resource/pubmed/id/10458618
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1999-9-7
|
pubmed:abstractText |
Immune functions represented by equal CD4 counts before and after highly active antiretroviral therapy (i.e., pre- and post-HAART) in the same HIV-infected patients, were examined. Twelve HIV-infected patients were included. Patients had equal CD4 counts pre- and post-HAART and were studied on average 30 months pre-HAART and 17 months post-HAART. Post-HAART, CD8+ T cells expressed greater amounts of CD28 (p < .02), smaller amounts of CD38 (p < .02), and a reduced proportion of CD4+CD28+ T cells expressed CD38+ (p < .01). Proliferation increased (p < 10) in lymphocyte cell cultures stimulated with pokeweed mitogens or Candida, and was correlated to expression of CD28 on T cells (p < .02). The proportion of CD3-CD16-CD56+ natural killer (NK) cells increased (p < .05) and CD3-CD16+CD56- NK cells declined (p < .01). Production of interferon-gamma increased (p < .10). The number of naive and memory T cells, the non-major histocompatibility complex (non-MHC)-restricted and HIV-specific MHC-restricted cytotoxicity and the production of macrophage inflammatory protein-1gamma were unchanged. The finding of increased expression of CD28, correlating to increased proliferation capacity, and diminished expression of CD38 on T cells, indicates that following long-term HAART, repopulation occurs with less activated cells with increased proliferative capacity. This finding may be of clinical importance in considering risk and vulnerability for progression of opportunistic infections post-HAART.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
1525-4135
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
21
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
376-83
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10458618-Anti-HIV Agents,
pubmed-meshheading:10458618-Antigens, CD,
pubmed-meshheading:10458618-Biological Markers,
pubmed-meshheading:10458618-CD4 Lymphocyte Count,
pubmed-meshheading:10458618-Cells, Cultured,
pubmed-meshheading:10458618-Disease Progression,
pubmed-meshheading:10458618-Drug Therapy, Combination,
pubmed-meshheading:10458618-Follow-Up Studies,
pubmed-meshheading:10458618-HIV Infections,
pubmed-meshheading:10458618-HIV Protease Inhibitors,
pubmed-meshheading:10458618-Humans,
pubmed-meshheading:10458618-Immunophenotyping,
pubmed-meshheading:10458618-Lymphocyte Activation,
pubmed-meshheading:10458618-Male,
pubmed-meshheading:10458618-T-Lymphocyte Subsets,
pubmed-meshheading:10458618-Time Factors
|
pubmed:year |
1999
|
pubmed:articleTitle |
Immune function and phenotype before and after highly active antiretroviral therapy.
|
pubmed:affiliation |
Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Denmark.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|